Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Non-randomised, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects

Next Previous
Trial Profile

Open-label, Non-randomised, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanimilast (Primary)
  • Indications Allergic asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici SpA

Most Recent Events

  • 22 May 2024 Results assessing systemic exposure and safety in subjects with mild, moderate, and severe renal impairment (RI) after single dose administration of tanimilast presented at the 120th International Conference of the American Thoracic Society
  • 25 Jan 2023 Status changed from recruiting to completed.
  • 01 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top